X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHI's Protein Engineering Summit

Advancements Support Two Internal and Four Alliance Therapeutic Programs

News provided by

X-BODY BioSciences

27 Apr, 2012, 09:30 ET

WALTHAM, Mass., April 27, 2012 /PRNewswire/ -- X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced it will present novel methods of selecting for antibodies against targets on the surface of live cells at CHI's Protein Engineering Summit (PEGS) and the associated Biologics Partnering Forum being held April 28th through May 4th in Boston, Massachusetts. 

Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY, will present a talk entitled, "Predicting Antibody Binding Properties by Interrogation of Fully Human Libraries with Deep Sequencing" on Saturday, April 28th at 4:15 PM.

Yan Chen, M.D./Ph.D., Senior VP of Research and Development at X-BODY, will present a talk entitled, "Generation and Optimization of Fully Human VH Domain Antibodies and IgG Using dsDNA Display with Deep Sequence Hit Analysis" on Tuesday, May 1st at 3:05 PM. 

A poster entitled, "Selection of Fully Human Antibodies Targeting HER2 Expressed on Live Cells with dsDNA Display and Massively Parallel Deep Sequencing Analysis" will also be presented by X-BODY at the conference on April 30th-May 1st.

X-BODY recently expanded its internal capabilities by hiring an expert team in performing live cell screening, deep sequence bioinformatics, and engineering.  X-BODY's novel proprietary system allows for performing antibody selections on live cells while simultaneously analyzing the cell binding characteristics of thousands of antibody hits.  X-BODY is now applying this live cell selection platform in four research alliances forged since January 2011 which are funded by X-BODY's research partners:  Alvos Therapeutics,  BioMed Valley Discoveries (established by the Stowers Institute for Medical Research), Tanabe Research Laboratories U.S.A., Inc. (an independent subsidiary of Mitsubishi Tanabe Pharma Corporation) and an undisclosed mid-cap biotechnology company.  X-BODY BioSciences has also applied live cell antibody selection technology to its internal programs in Oncology and Ophthalmology. 

About X-BODY BioSciences, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads.   The modular leads generated by X-BODY's platform can be incorporated into VH domain, scFv, IgG and bispecific antibody formats.    X-BODY's lead molecule, XB-2202, is a potent inhibitor of PDGF Receptor Beta and has potential applications in treating Age-Related Macular Degeneration (AMD) and solid tumors.    

WEB: www.x-bodybiosciences.com

SOURCE X-BODY BioSciences

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.